Reduction of plasma MicroRNA-21 is associated with chemotherapeutic response in patients with non-small cell lung cancer

Emerging studies have revealed that microRNA (miRNA) in body fluid may serve as a potential biomarker to detect non-small cell lung cancer (NSCLC). However, the diagnostic accuracy of miRNA for NSCLC detection is still under debate because there is inconsistency in previous studies. Hence, we conducted this meta-analysis to comprehensively evaluate the diagnostic performance of miRNA. A systematic literature search was performed to retrieve relevant articles in PubMed and other databases, and STATA 12.0 (StataCorp, College Station, TX, USA) was used to calculate the pooled parameters. A total of 28 articles involving 2121 NSCLC patients and 1582 healthy controls were included in this meta-analysis. The overall pooled sensitivity and specificity of miRNA were 0.75 and 0.79, respectively. The pooled positive likelihood ratio was 3.6, negative likelihood ratio was 0.32 and diagnostic odds ratio was 12. The area under the curve (AUC) was 0.84. Subgroup and meta-regression analyses established that miRNA assays were more accurate in Caucasian populations (AUC of 0.86, sensitivity of 0.79 and specificity of 0.82, respectively) than in Asian populations (AUC, sensitivity and specificity of 0.83, 0.72 and 0.80, respectively). In addition, the multiple miRNA assays (AUC of 0.89, sensitivity of 0.83 and specificity of 0.82, respectively) showed a higher accuracy than single miRNA assays (AUC, sensitivity and specificity of 0.81, 0.77 and 0.71, respectively) in NSCLC detection. Subgroup analyses based on specimen types suggested that blood-based miRNA (AUC of 0.86, sensitivity of 0.78 and specificity of 0.80, respectively) may have a higher diagnostic accuracy as biomarkers than sputum-based miRNA (AUC of 0.81, sensitivity of 0.69 and specificity of 0.80, respectively). In conclusion, miRNA may serve as a potential biomarker in NSCLS detection, especially the multiple miRNA from blood, with a relatively high diagnostic accuracy.

show abstract

“…After full‐text reading by two reviewers, 39 failed to meet the inclusion criteria. Finally, 28 records were included in the meta‐analysis …”

Section: Resultsmentioning

confidence: 99%

Clinical use of microRNAs as potential non‐invasive biomarkers for detecting non‐small cell lung cancer: A meta‐analysis

Wang

Zhao

et al. 2014

Respirology

View full text Add to dashboard Cite

show abstract

“…Most studies selected miRNAs by microarray [ 12 , 13 , 18 , 21 , 22 , 24 , 26 – 28 , 34 – 37 , 39 , 41 , 42 , 46 – 49 , 52 , 55 , 59 , 61 , 64 , 67 , 74 ]. Some identified miRNAs by literature [ 11 , 14 – 16 , 19 , 23 , 25 , 29 – 33 , 40 , 43 – 45 , 50 , 51 , 53 , 54 , 56 – 58 , 60 , 62 , 63 , 65 , 66 , 68 – 73 , 75 , 84 ]. To give an insight to future studies, we listed the potential miRNAs reported by literature that could serve as circulating biomarkers.…”

Section: Discussionmentioning

confidence: 99%

The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers

Yang

Zhou

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Many studies have investigated the diagnostic role of circulating microRNAs (miRNAs) in patients with lung cancer; however, the results still remain inconclusive. An updated system review and meta-analysis was necessary to give a comprehensive evaluation of diagnostic role of circulating miRNAs in lung cancer. Eligible studies were searched in electronical databases. The sensitivity and specificity were used to plot the summary receiver operator characteristic (SROC) curve and calculate the area under the curve (AUC). The between-study heterogeneity was evaluated by Q test and I2 statistics. Subgroup analyses and meta-regression were further performed to explore the potential sources of heterogeneity. A total of 134 studies from 65 articles (6,919 patients with lung cancer and 7,064 controls) were included for analysis. Overall analysis showed that circulating miRNAs had a good diagnostic performance in lung cancers, with a sensitivity of 0.83, a specificity of 0.84, and an AUC of 0.90. Subgroup analysis suggested that combined miRNAs and Caucasian populations may yield relatively higher diagnostic performance. In addition, we found serum might serve as an ideal material to detecting miRNA as good diagnostic performance. We also found the diagnostic role of miRNAs in early stage lung cancer was still relatively high (the sensitivity, specificity and an AUC of stage I/II was 0.81, 0.82 and 0.88; and for stage I, it was 0.80, 0.81, and 0.88). We also identified a panel of miRNAs such as miR-21-5p, miR-223-3p, miR-155-5p and miR-126-3p might serve as potential biomarkers for lung cancer. As a result, circulating miRNAs, particularly the combination of multiple miRNAs, may serve as promising biomarkers for the diagnosis of lung cancer.

show abstract

“…Recent studies have shown that dysregulation of miRNA expression contributes to the development and progression of cancer (26)(27)(28). miRNA profiles can also be used as biomarkers for detection of cancer (29)(30)(31)(32)(33)(34) and to predict chemotherapeutic response (35)(36)(37)(38). It is therefore of particular interest to investigate the therapeutic application of miRNAs in lung cancer.…”

Section: Discussionmentioning

confidence: 99%

miR-608 regulates apoptosis in human lung adenocarcinoma via regulation of AKT2

Othman

Nagoor

2017

International Journal of Oncology

View full text Add to dashboard Cite

Lung cancer remains a major health problem with a low 5-year survival rate of patients. Recent studies have shown that dysregulation of microRNAs (miRNAs) are prevalent in lung cancer and these aberrations play a significant role in the progression of tumour progression. In the present study, bioinformatics analyses was employed to predict potential miR-608 targets, which are associated with signaling pathways involved in cancer. Luciferase reporter assay identified AKT2 as a novel target of miR-608, and suppression of its protein levels was validated through western blot analysis. Zebrafish embryos were microinjected with cells transfected with miR-608 to elucidate the role of miR-608 in vivo, and immunostained with antibodies to detect activated caspase-3. We present the first evidence that miR-608 behaves as a tumour suppressor in A549 and SK-LU-1 cells through the regulation of AKT2, suggesting that selective targeting of AKT2 via miR-608 may be developed as a potential therapeutic strategy for miRNA-based non-small cell lung cancer (NSCLC) therapy.

show abstract

Reduction of plasma MicroRNA-21 is associated with chemotherapeutic response in patients with non-small cell lung cancer

Cited by 28 publications

References 45 publications

Clinical use of microRNAs as potential non‐invasive biomarkers for detecting non‐small cell lung cancer: A meta‐analysis

Clinical use of microRNAs as potential non‐invasive biomarkers for detecting non‐small cell lung cancer: A meta‐analysis

The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers

miR-608 regulates apoptosis in human lung adenocarcinoma via regulation of AKT2

Contact Info

Product

Resources

About